In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202

Clinical Cancer Research

Volumn 11, Issue 13, 2005, Pages 4875-4888

  Raynaud, Florence I ^a   Whittaker, Steven R ^a   Fischer, Peter M ^b   McClue, Steven ^b   Walton, Michael I ^a   Barrie, S Elaine ^a   Garrett, Michelle D ^a   Rogers, Paul ^a   Clarke, Simon J ^a   Kelland, Lloyd R ^a   Valenti, Melanie ^a   Brunton, Lisa ^a   Eccles, Suzanne ^a   Lane, David P ^b   Workman, Paul ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b CYCLACEL LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BOHEMINE; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLINE; MOLECULAR MARKER; OLOMOUCINE; PURINE DERIVATIVE; RETINOBLASTOMA PROTEIN; RNA POLYMERASE II; ROSCOVITINE; SULFORHODAMINE B; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASSAY; CANCER INHIBITION; CELL STRAIN HCT116; COLON CARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG EXPOSURE; DRUG POTENCY; DRUG TUMOR LEVEL; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOUSE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; AREA UNDER CURVE; BLOTTING, WESTERN; CDC2 PROTEIN KINASE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASES; ENZYME INHIBITORS; FEMALE; HCT116 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; KINETIN; MAXIMUM TOLERATED DOSE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; PHOSPHORYLATION; PURINES; RECOMBINANT PROTEINS; RETINOBLASTOMA PROTEIN; TIME FACTORS; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 27644591251     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-2264     Document Type: Article

References (52)

1. Sherr CJ. Cancer cell cycles. Science 1996;274:1672-7.
2. Sherr CJ. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res 2000;60:3689-95.
3. Porter PL, Malone KE, Heagerty PJ, et al. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 1997;3:222-5.
4. Tsihlias J, Kapusta L, Slingerland J. The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer. Annu Rev Med 1999;50:401-23.
5. Fry DW, Garrett MD. Inhibitors of cyclin-dependent kinases as therapeutic agents for the treatment of cancer. Current Opinion in Oncologic. Endocrine and Metabolic Investigational Drugs 2000;2:40-59.
6. Sausville EA. Complexities in the development of cyclin-dependent kinase inhibitor drugs. Trends Mol Med 2002;8:S32-7.
7. Tetsu O, McCormick F. Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell 2003;3:233-45.
8. Chen YN, Sharma SK, Ramsey TM, et al. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc Natl Acad Sci U S A 1999;96:4325-9.
9. Mendoza N, Fong S, Marsters J, Koeppen H, Schwall R, Wickramasinghe D. Selective cyclin-dependent kinase 2/cyclin A antagonists that differ from ATP site inhibitors block tumor growth. Cancer Res 2003;63:1020-4.
10. Vesely J, Havlicek L, Strnad M, et al. Inhibition of cyclin-dependent kinases by purine analogues. Eur J Biochem 1994;224:771-86.
11. De Azevedo WF, Leclerc S, Meijer L, Havlicek L, Strnad M, Kim SH. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. Eur J Biochem 1997;243:518-26.
12. Wang S, McClue SJ, Ferguson JR, et al. Synthesis and configuration of the cyclin-dependent kinase inhibitor roscovitine and its enantiomer. Tetrahedron: Asymmetry 2001;12:2891-4.
13. McClue SJ, Blake D, Clarke R, et al. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int J Cancer 2002;102:463-8.
14. Meijer L, Borgne A, Mulner O, et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem 1997;243:527-36.
15. Whittaker SR, Wallon MI, Garrett MD, Workman P. The cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway. Cancer Res 2004;64:262-72.
16. Schutte B, Nieland L, van Engeland M, Henfling ME, Meijer L, Ramaekers FC. The effect of the cyclin-dependent kinase inhibitor olomoucine on cell cycle kinetics. Exp Cell Res 1997;236:4-15.
17. Wang S, Meades C, Wood G, et al. 2-Anilino-4-(thiazol-5-yl)pyrimidine CDK inhibitors: synthesis, SAR analysis, X-ray crystallography, and biological activity. J Med Chem 2004;47:1662-75.
18. 2 arrest after DNA damage. Science 1998;282:1497-501.
19. Kelland LR, Murrer BA, Abel G, Giandomenico CM, Mistry P, Harrap KR. Ammine/amine platinum(IV) dicarboxylates: a novel class of platinum complex exhibiting selective cytotoxicity to intrinsically cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res 1992;52:822-8.
20. Workman P, Twentyman P, Balkwill F, et al. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia (second edition). Br J Cancer 1998;77:1-10.
21. Gabrielsson J, Weiner D. Pharmacokinetic and pharmacodynamic data analysis, concepts and applications. 2nd ed. Swedish Pharmaceutical Press; 1997. Stockholm, Sweden.
22. Tamrakar S, Mittnacht S, Ludlow JW. Binding of select forms of pRB to protein phosphatase type 1 independent of catalytic activity. Oncogene 1999;18:7803-9.
23. Barrie SE, Eno-Amooquaye E, Hardcastle A, et al. High-throughput screening for the identification of small-molecule inhibitors of retinoblastoma protein phosphorylation in cells. Anal Biochem 2003;320:66-74.
24. Mellish KJ, Kelland LR. Mechanisms of acquired resistance to the orally active platinum-based anticancer drug bis-acetato-ammine-dichlorocyclohexylamine platinum (iv.) (JM216) in two human ovarian carcinoma cell lines. Cancer Res 1994;54:6194-200.
25. Sharp SY, Rowlands MG, Jarman M, Kelland LR. Effects of a new antioestrogen, idoxifene, on cisplatin- and doxorubicin-sensitive and -resistant human ovarian carcinoma cell lines. Br J Cancer 1994;70:409-14.
26. Ashizawa S, Nishizawa H, Yamada M, et al. Collective inhibition of pRB family proteins by phosphorylation in cells with p16INK4a loss or cyclin E overexpression. J Biol Chem 2001;276:11362-70.
27. Thompson AM, Steel CM, Chetty U, et al. p53 gene mRNA expression and chromosome 17p allele loss in breast cancer. Br J Cancer 1990;61:74-8.
28. Fisher RP, Morgan DO. A novel cyclin associates with MO15/CDK7 to form the CDK-activating kinase. Cell 1994;78:713-24.
29. Gayet J, Zhou XP, Duval A, et al. Extensive characterization of genetic alterations in a series of human colorectal cancer cell lines. Oncogene 2001;20:5025-32.
30. Garrett MD, Wallon MI, McDonald E, Judson I, Workman P. The contemporary drug development process: advances and challenges in preclinical and clinical development. Prog Cell Cycle Res 2003;5:145-58.
31. Workman P. Challenges of PK/PD measurements in modern drug development. Eur J Cancer 2002;38:2189-93.
32. Workman P. How much gets there and what does it do?: the need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development. Curr Pharm Des 2003;9:891-902.
33. 2 phase roles for Cdk2 revealed by inducible expression of a dominant-negative mutant in human cells. Mol Cell Biol 2001;21:2755-66.
34. Lam LT, Pickeral OK, Peng AC, et al. Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol 2001;2:RESEARCH0041.
35. Bueno A, Russell P. Dual functions of CDC6: a yeast protein required for DNA replication also inhibits nuclear division. EMBO J 1992;11:2167-76.
36. Byrd PJ, Cooper PR, Stankovic T, et al. A gene transcribed from the bidirectional ATM promoter coding for a serine rich protein: amino acid sequence, structure and expression studies. Hum Mol Genet 1996;5:1785-91.
37. Chen PL, Scully P, Shew JY, Wang JY, Lee WH. Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation. Cell 1989;58:1193-8.
38. Gao G, Bracken AP, Burkard K, et al. NPAT expression is regulated by E2F and is essential for cell cycle progression. Mol Cell Biol 2003;23:2821-33.
39. Hua XH, Newport J. Identification of a preinitiation step in DNA replication that is independent of origin recognition complex and cdc6, but dependent on cdk2. J Cell Biol 1998;140:271-81.
40. Imai T, Yamauchi M, Seki N, et al. Identification and characterization of a new gene physically linked to the ATM gene. Genome Res 1996;6:439-47.
41. Imai T, Sugawara T, Nishiyama A, et al. The structure and organization of the human NPAT gene. Genomics 1997;42:388-92.
42. Jiang W, Wells NJ, Hunter T. Multistep regulation of DNA replication by Cdk phosphorylation of HsCdc6. Proc Natl Acad Sci U S A 1999;96:6193-8.
43. Krek W, Xu G, Livingston DM. Cyclin A-kinase regulation of E2F-1 DNA binding function underlies suppression of an S phase checkpoint. Cell 1995;83:1149-58.
44. Ma T, Van Tine BA, Wei Y, et al. Cell cycle-regulated phosphorylation of p220(NPAT) by cyclin E/Cdk2 in Cajal bodies promotes histone gene transcription. Genes Dev 2000;14:2298-313.
45. Petersen BO, Lukas J, Sorensen CS, Bartek J, Helin K. Phosphorylation of mammalian CDC6 by cyclin A/CDK2 regulates its subcellular localization. EMBO J 1999;18:396-410.
46. Shan B, Farmer AA, Lee WH. The molecular basis of E2F-1/DP-1-induced S-phase entry and apoptosis. Cell Growth Differ 1996;7:689-97.
47. Zhao H, Piwnica-Worms H. ATR-mediated check-point pathways regulate phosphorylation and activation of human Chk1. Mol Cell Biol 2001;21:4129-39.
48. Zhao J, Dynlacht B, Imai T, Hori T, Harlow E. Expression of NPAT, a novel substrate of cyclin E-CDK2, promotes S-phase entry. Genes Dev 1998;12:456-61.
49. Nutley BP, Raynaud F, Wilson SC, et al. Metabolism and pharmacokinetics of the cyclin dependent kinase inhibitor CYC202 in the mouse. Mol Cancer Ther 2004;4:125-39.
50. de la MS, Gianella-Borradori A. Pharmacokinetic model of R-roscovitine and its metabolite in healthy male subjects. Int J Clin Pharmacol Ther 2004;42:232-9.
51. Raymond E, Laurence V, Faivre S, et al. Proc AARC-NCI-EORTC Mol Targets Cancer Ther 2002;13 Abs 150.
52. Guzi T. CYC-202. Curr Opin Investig Drugs 2004;5:1311-8.